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Abstract
The role of immune system in our body is to defense against the foreign bodies. 
However, if the immune system fails to recognize self and non-self-cells in our body 
leads to autoimmune diseases. Widespread autoimmune diseases are rheumatoid 
arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, and more 
yet to be added to the list. This chapter discusses about how stem cell-based therapies 
and advancement of regenerative medicine endow with novel treatment for autoim-
mune diseases. Furthermore, in detail, specific types of stem cells and their thera-
peutic approach for each autoimmune condition along with their efficiency to obtain 
desired results are discussed. Ultimately, this chapter describes the recent trends in 
treating autoimmune diseases effectively using advanced stem cell research.
Keywords: autoimmune disease, stem cell therapy, regenerative medicine, 
hematopoietic stem cell lines, mesenchymal stem cells, rheumatoid arthritis
1. Introduction
Autoimmune disease [AID also called as autoimmune disorder] is a result 
of immunological imbalance and intolerance. In such a condition, an immune 
response is produced against the healthy tissues or substances present in our own 
body [1]. Though, there were roughly 67 autoimmune diseases known as per the 
reporting of American Autoimmune Related Disease Association [AARDA] in 1992 
with 40 in suspicion, the number has grown to be in a range of 150 AID in 2016. 
With such a rapid incidence, AID has an impact on the social status and economy 
of the country too. With a mean age of onset at 65, AID targets the age group of 
20–29 [2]. Gender-based studies continue to be a conundrum due to biased data 
reports and sexual dimorphism [3]. A series of events trigger AID, but the trig-
ger that causes such a holocaust still remains unknown. Environmental factors, 
 misregulation of immune system, and heredities are few common factors that influ-
ence AID out of the humungous list. Smoking, alcohol, industrial pollution, oral 
contraceptives, birth weight, breastfeeding, protein intake, geography, and socio-
economic status are some of the possible environmental triggers associated with 
AID. In case of misregulation of genes, the association of human leucocyte antigen 
(HLA) class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with 
several AIDs, including type 1 diabetes, Graves’ disease, and rheumatoid arthritis.
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2. Classification and types
AID is broadly classified into two types; systemic and organ specific. In systemic 
autoimmune disease, autoimmune response targets self-antigens that are distributed 
in various organs resulting in widespread tissue damage. Most affected areas include 
joints, skin, kidneys, heart, lungs, and red blood cells. On the other hand, antigens 
present over a particular organ are targeted in organ-specific autoimmune response 
[4]. Body parts that are affected by AID are represented in Figure 1. Prominent 
examples under both categories are considered and discussed in the following 
sections.
Current therapies lead to symptoms alleviation concomitant with side effects. 
Hence, stem cells can be a potential answer to the proposed conundrum by bridging 
the gap between the problem and the solution. The following section condenses on 
the therapeutic potential of stem cells.
3. Stem cells
With a lead role to play, stem cells have been superheroes in regenerative medi-
cine. Possessing the ability to self-renew, multilineage differentiation, mobility and 
homing, stem cells can treat many diseases by turning out to be any kind of cell 
through differentiation [5–8]. Stem cells can be classified into two major groups, 
Figure 1. 
Body parts affected by autoimmune disease condition.
Systemic Local disorders
Rheumatoid arthritis Endocrinology: diabetes mellitus
Systemic lupus erythematosus (SLE) Gastrointestinal: Crohn’s disease
Scleroderma Neurological: multiple sclerosis
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which include embryonic stem cells (ESC) and adult stem cells (ASC). Other 
type of stem cell is induced pluripotent stem cells [iPSCs] that can be produced 
in the laboratory by reprogramming adult cells to express embryonic stem cell 
characteristics.
3.1 Embryonic stem cells (ESCs)
ESCs are derived from an embryo approximately 3 days after fertilization with 
totipotency to give rise to more than 220 cell types in the future. ESCs face a criti-
cal reception due to complications such as rejection, directed differentiation, and 
source of ESCs. Method of obtaining ESCs involves the destruction of blastocysts 
and those who believe that life begins at the blastocyst is a human life, and to 
destroy that is unacceptable and immoral, this procedure is equally risk to female 
donors being consented [8].
3.2 Adult stem cells (ASCs)
ASCs are derived from the adult human body, precursor cells that can efficiently 
mend the body to help promoting homeostasis. Major accessible sources of ASCs 
include bone marrow, adipose tissues, and blood. Hematopoietic stem cells (HSCs) 
can differentiate into immune stem cells (multipotent) and all kinds of blood cells 
including white blood cells, red blood cells, and platelets [9].
3.3 Induced pluripotent stem cells (iPSCs)
iPSCs can be generated in the laboratory by introducing reprogramming factor 
in the somatic cells that express the defining properties of embryonic stem cells. 
This provides an opportunity to generate pluripotent patient-specific cell lines, to 
generate model for human disease, and also used as a tool for drug development. 
Moreover, the tissues derived from iPSCs are almost identical with the donor cells; 
thus, it avoids the major rejection issue arose by the immune system [10].
3.4 Stem cells and their timeline
Once the Second World War came to an end, the world turned its concentration 
from research in destructive and nuclear weapons toward welfare of the human race 
after NATO. When such a scenario occurred and scientists started working on the 
betterment of human race, a path was paved for research on stem cells. The following 
table is a timeline containing significant events pertaining to stem cells [11, 12].
Year Significant endeavors
1963 Self-renewing property of transplanted mouse bone marrow cells were first documented by 
Canadian researchers Ernest A McCulloch and James E Till
1968 First bone transplant was performed for leukemia
1978 Discovery of stem cell in human cord blood
1981 Embryonic stem cells were isolated from mice
1988 Embryonic stem cell lines generated from a hamster
1995 First embryonic stem cell line was derived from a primate
1996 First British and European stem cell company (ReNeuron) emerged
1997 Cloned lamb from stem cells
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4. Action of stem cells on AID
Hematopoietic stem cells (HSCs) were first employed to serve as a solution to 
leukemia and lymphoma. Eventually, after conducting trials over animal model 
experiments, hematopoietic stem cells found its application in destruction of 
self-reactive memory cells and in regeneration of self-tolerant immune cells; hence 
Year Significant endeavors
1997 Leukemia origin was found as hematopoietic stem cell, thus indicated a possible proof of cancer 
stem cells
1998 James Alexander Thomson and his team cultivated the first human embryonic stem cells in a 
laboratory dish
1999–
2000
Scientists discovered that manipulating adult mouse tissues could produce different cell types 
indicates bone marrow cells could produce different type of other cells
2001 For the first-time Christine Mummery and her team used stem cells to create beating heart cells 
outside the body
2002 Chunhui Xu and team found that heart muscle cells can be made from human embryonic stem 
cells
2003 Antonio Beltrami described a small population of stem cells in the heart that help in repair itself 
after damage
2004 Valérie Planat-Bénard and colleagues found that heart-like cells could be heart-like cells could be 
cultivated from adipose tissue
2004 First UK Stem Cell Bank (UKSCB) accredited
2006 Shinya Yamanaka of Japan reprogrammed adult cells and formed “induced pluripotent stem cells”
2007 Anthony Atala claimed that a new type of stem cell had been isolated in amniotic fluid
2007 Direct transformation of Human skin cells to iPS cells found by Shinya Yamanaka has become the 
revolutionary breakthrough in stem-cell biology
2009 Cardio 3 bioscience company performed lineage guided Stem cell transplant for heart failure and 
heart attack
2010 Geron company conducted first clinical trial for spinal cord injury and two successful 
human embryonic stem cell trials were conducted by Advanced Cell Technology for macular 
degeneration
2011 Geron terminated hESC trials and first hESC cell lines were generated
2012 Human embryonic stem cells show promising treatment for blindness
2013 -Advanced cell technology and Cardio 3 bioscience published clinical results
-Brainstorm demonstrates positive results in phase 1 and phase 2 clinical trials
-Aastrom-terminated phase 3 clinical study conducted for critical limb ischemia
-Patient-specific human embryonic stem cells were produced
2013 Shoukhrat Mitalipov produce hESCs from fetal cells
2014 Masayo Takahashi performed the world’s first trial for iPSC derived transplant to treat a form of 
age-related blindness
2014 Charles Vacanti Haruko Obokata at the Riken Center for Developmental Biology announced a 
breakthrough discovery of the concept pre-embryonic state.
Dieter Egli of the New York Stem Cell Foundation and Young Gie Chung from CHA University 
independently produce hESCs from adult cells, using therapeutic cloning
2016 Jo Mountford and the University of Glasgow, culturing red blood cells from stem cells to make a 
limitless supply of clean blood for transfusion
2019 Xuefei Gao et al. for the first time derived the Expanded Potential Stem Cell lines (EPSCs) of pig 
and human cells which has the important implications for developmental biology, regenerative 
medicine, organ transplantation, disease modeling, and screening for drugs
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constructing a new functional immune system from hematopoietic precursors. HSC 
transplantation has been used to treat several types of AID over the past 15 years 
with a 30% decline in the progress of the AID [13–15].
Mesenchymal stem cells (MSCs) were another kind of multipotent stromal cells 
that were almost omnipotent, discovered by Frienden Stein et al. Being immuno-
suppressive, MSCs were found to suppress inflammation and downregulate patho-
genic immune response triggered in Graft versus Host Disease (GVHD) and in AID 
such as multiple sclerosis, autoimmune diabetes, and rheumatoid arthritis [16, 17].
4.1 Hematopoietic stem cell transplantation
HSC transplantation to treat AID has been in progress since 1970s. HSCs are 
typically obtained from bone marrow, peripheral blood, or umbilical cord blood. 
Source of HSC may be autologous or allogeneic. Differentiation of hematopoietic 
stem cells into all kinds of blood and immune stem cells is represented in Figure 2.
4.1.1 Isolation of HSCs
Stem cells are mobilized from the bone marrow to peripheral blood, which 
will facilitate the collection of HSCs without general anesthesia or bone marrow 
harvest. The method of mobilization can be done by a variety of protocols. Majorly 
protocols make use of granulocyte colony stimulating factor or cyclophosphamide. 
Cyclophosphamide leads to rebound mobilization of stem cells as it is both immu-
nosuppressive and myelosuppressive. Leukapheresis is used to collect the HSCs and 
purification is done by identifying stem cell containing CD34+ markers or lineage-
specific surface markers by negative selection of T or B cells. Negative selection 
process leads to T cell depletion in the auto graft [18, 19].
While isolation was first performed in murine model, efforts have been made to 
develop human models. Fluorescence-activated cell sorting (FACS) has been employed 
Figure 2. 
Differentiation of multipotent hematopoietic stem cells.
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for isolation, recognition, and quantification of smaller number of cells in a huge popu-
lation. The technique is so accurate that there is a cent percent probability in purity [20].
4.1.2 Autologous HSC transplantation
Autologous HSC transplantation has been used to treat several AIDs such as 
rheumatoid arthritis, multiple sclerosis, Sjögren’s syndrome, and systemic lupus 
erythematosus. As the name suggests, autologous HSC transplantation uses the sub-
ject’s own stem cell avoiding tissue rejection. This kind of transplantation eradicates 
autoreactive immunologic memory through conditioning with highly active cyto-
toxic agents. Then, B and T cells can be introduced to auto antigens and undergo 
self-tolerance; in contrast, environmental factors that trigger autoimmunity might 
not occur again throughout the subject’s lifetime [21–24]. The step wise protocol for 
autologous stem cell transplantation is depicted in Figure 3.
4.1.3 Allogenic HSC transplantation
Allogenic transplantation is done between two subjects whose human leucocyte 
antigen (HLA) match. Even though the HLA gene matches, the recipient will 
undergo immunosuppressive medications to tone down graft-versus-host disease. 
In this type, the donor may be closely related, syngeneic (identical twin of the 
patient) or may be unrelated but with HLA match. In allogeneic HSCTs process, 
the healthy stem cells are transferred to the recipient’s bloodstream to reform a 
healthy immune system and this method appears to improve chances for cure and 
in long-term remission. However, there were also cases of rheumatoid arthritis 
subjects affected by drug-induced aplastic anemia, where relapse occurred since all 
the immune competent cells were from the donor [25–28]. Autoimmunity is treated 
using HSC transplantation and the following are the action of HSCs:
Figure 3. 
Autologous stem cell transplantation.
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1. Developing tolerance by T regulatory cells.
2. Developing tolerance of autoreactive and alloreactive B cells.
3. Deleting alloreactive and autoreactive T cells in thymus.
4. Deleting peripheral autoreactive and alloreactive T cells.
5. Destruction of autoreactive B cells and T cells mediated by the immune system.
6. Immunosuppressive conditioning and autogenic HSC transplantation leading 
to immunomodulation.
The step wise protocol in allogeneic stem cell transplantation is represented in 
Figure 4.
4.2 Mesenchymal stem cell transplantation
MSCs possess the ability to differentiate both in-vivo and in-vitro into different 
lineages, which include adipose, bone, cartilage, muscle, and myelosupportive 
stroma (Figure 5) [29]. Isolation of MSCs can be done from bone marrow, skeletal 
muscle, adipose tissue synovial membranes, connective tissues in adults, cord 
blood, and products of placenta; each of which is defined by using phenotypic 
markers and their functional properties [12, 30–32]. Allogeneic MSCs can be trans-
planted into a patient without preconditioning and still have positive clinical effects 
on the subject without acute toxicity [33, 34]. MSCs possess the following abilities 
that make them a clinical success [35].
1. Homes to inflammation site when delivered intravenously following tissue 
injury.
2. Differentiates into a variety of cells.
3. Secretes multiple bioactive molecules that facilitate recovery of injured cells 
and inhibition of inflammation in return.
4. Lacks immunogenicity and possess immunomodulatory functions.
Figure 4. 
Allogeneic stem cell transplantation.
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MSCs can also migrate and engraft at the inflammation site, when administered 
locally or systemically [36, 37]. Various cases of such an ability is discussed in the 
below paragraph.
Ortiz et al. found that murine MSCs could respond during a lung injury, 
ameliorating inflammation while adopting epithelium-like phenotype; when mice 
were injected with bleomycin [38]. Liu et al. found that MSCs could migrate to the 
site of injury in muscle tissues [39]. Yagi et al. found that the migration of MSCs 
was influenced by a variety of tyrosine kinase growth factor receptors such as 
platelet derived growth factor (PDGF) and IGF-1 and chemokines such as CCR2, 
CCR3, CCR4, or CCL5. Chemokines were found to lessen migration of MSCs in in 
vitro migration assays. MSCs are more privileged as they express low levels of HLA 
class I and HLA class II, CD40, CD80, and CD86 cannot be detected on the cell 
surface. Class I and class II molecules were found to increase when stimulated with 
interferon; thus, facilitating an increased efficiency of MSCs by being immuno-
suppressive and possessing immunological friendly phenotype [40, 41].  
Animal models of experimental autoimmune encephalomyelitis were found to be 
successfully treated with MSCs, while the case was hazardous in collagen-induced 
arthritis (CIA). Autologous bone marrow-derived MSCs were found to be anti-
proliferative toward stimulated T cells derived from normal subjects and AID 
subjects [42–44].
4.2.1 Isolation of MSC
Markers such as CD44, CD73, CD90, and CD105 for MSCs with the lack of 
CD14, CD31, CD33, CD34, and CD45 are used for isolating MSCs using cytofluoro-
metric analysis. Due to their heterogeneity, the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy (ICST) published three 
minimal criteria for MSCs [35]:
• MSCs should adhere to plastic when in standard culture conditions.
• Display of surface antigen expression pattern including CD73+, CD901+, 
CD105+, CD34−, CD45−, CD11b−, CD14−, CD19−, CD79a−, HLA-DR−.
• MSCs must be multipotent with the ability to differentiate into osteogenic, 
chondrogenic, and adipogenic lineage.
Figure 5. 
Mesenchymal stem cell differentiation.
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4.2.2 Autologous and allogeneic MSC therapy
MSC therapy has been widely applied and two different modes of therapy are dis-
cussed below. Isolation of cells is done based on the markers stated above and the cells 
are delivered using two approaches: intravenous and intra-arterial injection. In intra-
venous injection, the MSCs migrate to the affected site and can stay up to 13 months 
in the body. Moreover, route of administration is chosen based on the application 
used to resolve [45]. Autologous MSCT is obtained from self, while allogeneic MSCT 
is performed between individuals whose HLA expressions match. Both autologous 
and allogeneic MSC therapies are used to subside inflammation and hence are used to 
treat disease such as systemic lupus erythematosus, Crohn’s disease, multiple system 
atrophy, multiple sclerosis, amyotrophic lateral sclerosis, and stroke [46].
4.2.3 MSC over HSC
HSCs have been associated with the risk of Graft versus Host Disease (GVHD). 
On the other hand, conducted preclinical studies prove that MSCs were successful. 
When MSCs were infused intravenously in leukemia subjects who were grafted 
with HSCs, the GVHD incidence was found to be loud (4). GVHD is suppressed by 
secretion of transforming growth factor β (TGF-β), prostaglandin E2, and indole-
amine 2,3-dioxygenase, which in turn suppresses T cell proliferation and activation. 
Hence, MSCs were found to be compatible rather than HSCs.
5. Application of stem cells to treat AID
5.1 Systemic AID
Systemic autoimmune diseases are broad range of related diseases characterized 
by misregulation of immune system that gives rise to activation of immune cells and 
attack auto antigens, which result in multi-tissue/organ damages. In the following 
section, prominent examples of systemic AID and their therapy with stem cells are 
discussed briefly with proven animal model and clinical studies.
5.1.1 Rheumatoid arthritis (RA)
RA affects approximately 1.5% of the world population, and it is characterized 
by chronic joint inflammation, production of auto antibodies accompanied with 
various degrees of bone, and cartilage erosion triggered due to immunological 
self-intolerance [47–49]. It is a multifactorial disease, results from the combination 
of misregulation of genetic factor, immune system, and environmental exposure. 
However, the precise underlying mechanism of RA is not clear. In RA subjects, 80% 
of them comprise rheumatoid factor, an auto antibody specific to the Fc region of 
the IgG. There is no clear evidence about the source of inflammatory cytokines in 
specific stem cells. However, on contrast, RA can be transmitted as well as abolished 
by allogenic and autologous hematopoietic stem cell transplantation [50].
5.1.2 Current treatment methods
Current treatment methods include drugs, therapies, and surgeries. Drugs 
such as steroids and nonsteroidal anti-inflammatory drugs (NSAID); and disease-
modifying antirheumatic drugs (DMARD) such as methotrexate, leflunomide, and 
plaquenil to slacken the progression of the disease and biological DMARD. Therapy 
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includes cryotherapy, short wave or microwave diathermy, and physiotherapy. Heat 
and cold treatment can soothe pain. Surgery such as total knee replacement, tendon 
repair, or joint infusion is done according to the magnitude and site of damage.
Current therapy includes the use of hematopoietic stem cell transplant and mes-
enchymal stem cell transplant. However, recurrence was found to occur in majority 
of the cases irrespective of CD34+ graft selection. Preclinical studies were performed 
and the trial consisted of three phases. The first two phases were found to establish 
potential characterization of the technique with high dose chemotherapy within safety 
limits. Improved response was noted with increased doses in the conditioning regimen 
and with post SCT therapy was studied but the graft manipulation was not taken into 
consideration. Phase three was attempted with widespread use of biological anti-rheu-
matic agents. Autologous SCT is considered in rare subjects, who resist both conven-
tional and biological treatments [51, 52]. Figure 6 represents the treatment method 
for rheumatoid arthritis using allogeneic mesenchymal stem cell transplantation.
5.1.2.1 Animal model study
Gonzalez et al. performed the study over a mice model. Injection of adipose-
derived MSCs was followed by the decrease in inflammatory cytokines and chemo-
kines with an expansion of Th1/Th17 cells and increase in IL-10. Together, it was 
found to induce peripheral tolerance by controlling self-antigen reactive T cells. 
Further, an increase in CD4+, CD25+, Fox P3+, T-reg led to the suppression of self-
reactive response. Other studies described the differences between in vivo and in 
vitro studies. In in vitro studies show that MSCs inhibit T cell proliferation by regu-
lating IFN-γ levels while in vivo studies show that the transplantation did not have 
an effect on the progression of the disease. The real complication lies in the MSCs 
reaching the lymph and spleen nodes when injected [53]. Bouffi et al. demonstrated 
that the MSCs had an immunosuppressive effect involving a pathway regulated by 
prostaglandin 2. There were also evidences showing that T-reg cell induction was not 
influenced by the MSCs and hence choosing a different age group for the mice used 
in the study could have been a factor for the complications listed previously [43].
5.1.2.2 Intra-bone marrow-bone marrow transplantation (IBM-BMT)
SKG/Jcl mouse with T cell-mediated AD that mimics RA. BM cells of C57BL/6 J 
mice were transplanted to SKG/Jcl mice and there was no incidence of arthritis for 
Figure 6. 
Treatment method for rheumatoid arthritis using allogeneic mesenchymal stem cell transplantation.
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12 months with replacement of hematolymphoid cells with the donors’ cells. IBM-
BMT is a viable method and lends further credit to be tested in humans [54, 55].
5.1.2.3 Autologous stem cell transplantation (ASCT)
Elimination of mature autoreactive lymphocytes is done by manipulation of 
the graft by antithymocyte globulin (ATG) combined or with CD34+ by itself. The 
method basically depends on G-CSF and throughout the process, immunosuppres-
sion is done to introduce the SCs into the subject [56].
5.1.2.4 Clinical trial studies
Moore et al. conducted a study over 33 subjects and the subjects were randomly 
incident to autologous transplantation of non-manipulated cells or selected CD34+ 
cells. Non-manipulated stem cells were found to produce a better effect. Syngeneic 
transplantation of HSCs between twin brothers could control recurrence for at 
least 24 months. Healthy lymphocytes in a syngeneic transplantation could modify 
immunoregulation disorder. EBMT with 76 subjects out of which majority of the 
subjects responded well, but relapse rate was high [57, 58].
5.1.3 Systemic lupus erythematosus (SLE)
SLE is a rare chronic AD, which is characterized by upregulation of IFN-
regulated gene transcripts. In SLE, antibodies are generated against nuclear and 
cytoplasmic antigen. Autoreactive plasma cells play a major role in inducing 
SLE and hence short-lived plasma blasts are found in positive subjects. Reduced 
stem cell proliferation, BM dysfunction, and decline in CD34+ cells are associ-
ated with SLE. Hematopoietic system of SLE subjects had several defects due to 
the unbalanced expression of cytokines and growth factors. Transplantation of 
hematopoietic stem cells in MRL/lpr mice was found to reduce the occurrence. MSC 
transplantation was found to ameliorate the progression by inhibiting T lympho-
cytes and Th2 proliferation [59, 60].
5.1.3.1 Current treatment methods
Current treatment techniques include medication. The medication prescribed 
depends on the purpose served by the drug; disease modifying antirheumatic 
drugs, immunosuppressive drugs for immunomodulation, analgesics for analgesia, 
and intravenous immunoglobulins. In terminally ill cases, kidney transplant is an 
option while lesser silica, pesticides, and mercury levels can also have an impact on 
the subject. In recent years, hematopoietic stem cells and mesenchymal stem cells 
have been used for the drug-resistant SLE.
5.1.3.2 Animal model study
SLE animal model of W/BF1 mouse had a resultant decline in platelet count 
due to the production of anti-DNA antibodies and anti-platelet antibodies. These 
mice were found to possess lupus nephritis along with myocardial infarction, high 
WBC count, and hypertension. Transplantation of BM cells from normal mice was 
found to cure lupus nephritis, thrombocytopenia, and anti-phospholipid antibody 
syndrome. Normalization of platelet count was accompanied along with reduction 
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in antiplatelet antibody levels and anti-phospholipid levels. BMT along with thymus 
transplantation in MRL/Lpr mouse could treat AID as the allogeneic T cells were 
naïve T cells that were resistant to apoptosis with lesser Fas expression [61, 62].
5.1.3.3 Clinical studies
The first autologous hematopoietic stem cell transplantation for SLE was performed 
by Marmont et al. [62]. In this approach, peripheral CD34+ stem cell source was used 
after mobilization with CYC and granulocyte colony stimulating factor. According to 
European Group for Blood and Marrow Transplantation (EBMT), registry for HSCT in 
SLE patients showed around 80% of overall survival and 29% of disease-free survival 
and with a mortality rate of 15% suggests a goof efficacy and safety of autologous 
HSCT. In case of allogeneic HSCT, EBMT data showed that out of two patients, one 
patient died of infection and other had progressed disease after 3 years and thus clinical 
use of allogenic HSCT for SLE is limited. Mesenchymal stem cell transplantation was 
developed after 10 years of HSCT, and this approach showed a better efficacy with low 
cost compared to HSCT. Overall in the past 5 years, the advantage of stem cell therapies 
for SLE patients has increased tremendously with an initial development in high dose 
immunosuppression maintained by HSCT being followed by MSCT approach [63, 64].
5.1.4 Systemic scleroderma
Systemic sclerosis (SSc) is characterized by expansion of dysregulated fibroblast 
clones, which are uncontrollable and over expression of genes that constitute the 
extra cellular matrix, collagen type I in particular. SSc is characterized by high 
case-specific mortality as a result of internal organ disease and is also accompanied 
by other burdensome outcomes.
5.1.4.1 Classification
5.1.4.1.1 Limited (CREST syndrome)
Symptoms associated with limited syndrome are listed as follows.
• Raynaud’s phenomenon (vasoconstriction with less blood supply in the hands 
resulting with a color transition from red, white to blue in cold conditions).
• Calcinosis (calcium deposition occurs in the nodules).
• Dysfunctional esophagus promoting difficulty in swallowing.
• Clerodactyly (fingers have thickened skin).
• Telangiectasias (features such as dilated capillaries in hand, face and mucous 
membrane).
5.1.4.1.2 Diffuse (systemic sclerosis)
Diffuse scleroderma shows up mostly in organs such as kidney, esophagus, heart, 
and lungs. It is either combinational or occurs separately. It is more fatal when it 
occurs in the lungs. Symptoms mostly include changes in the skin within a year, fric-
tional rubs of tendons, lung, and GIT-associated complications, respectively [65, 66].
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5.1.4.2 Current treatment methods
Current treatment method only focuses on treating some of the symptoms that 
softens the skin and to lessen the inflammation condition, but is not completely 
curative and still remains as a puzzle. Some patients may get benefit by exposure 
to heat but non-lethal manifestations such as fatigue, calcinosis, and anorectal 
dysfunction still remains as a challenge.
5.1.4.3 Clinical trials with autologous stem cell transplant for early diffuse SSc
In the first trail, American Scleroderma Stem Cell versus Immune Suppression 
Trial (ASSIST), 10 patients who received autologous HSCT compared with 9 
patients who received 1.0 g/m2 intravenous CYC. Adverse events were poorly 
documented in this study, but seven of nine were worsened. In the second trail, 
Autologous Stem Cell Transplantation International Scleroderma (ASTIS) 79 
patients who received autologous HSCT compared with 77 patients who received 
750 mg/m2 IV CYC monthly for 12 months. This study results in higher mortal-
ity rate in the first year but had better long-term survival rate than those treated 
with CYC alone. The third trail scleroderma cyclophosphamide or transplantation 
(SCOT), 36 patients who received autologous HSCT compared with 39 patients 
given monthly IV CYC over 12 months. Despite the low numbers included in this 
study, the data demonstrated the efficacy of HSCT over CYC. Overall, the data 
provided by ASTIS and SCOT supports the HSCT over IV CYC [67, 68].
5.1.4.4 Clinical trial studies
A 16 year-old subject with localized scleroderma was selected. The subject 
possessed multiple plaque lesions along the trunk on 2008. By 2010, the subject had 
a progress in the condition involving the right half of the body further resulting 
in face asymmetry. Autologous HSCT was performed in 2011 by injecting fluda-
rabine, cyclophosphamide and equine anti-thymocyte globulin along with GCSF 
and acyclovir till engraftment. Supplemental dose of co-trimoxazole was given for 
prophylaxis, irradiated single donor platelets, and red blood cells for supportive 
care, respectively. No post transplantation complication was found and the subject 
was found to be stable with no progress in lesions after 41 months. The subject had 
no progress in the disease condition and no immunosuppression was done once the 
transplantation came to an end [69].
6. Organ-specific AID
The following section discusses prominent examples in Organ specific AID and 
their association with stem cells.
6.1 Type 1 diabetes (T1D)
T1D is an autoimmune disease with a strong genetic component that tends 
to occur in childhood. As of 2014, an estimated 387 million people have diabetes 
worldwide, out of which T1D accounts for 5–10% worldwide. Characterized by the 
destruction of insulin-producing β cells by the auto antibody directed against it. 
Hence, introduction of insulin or islet replacement is necessary for homeostasis by 
regulating sugar levels [70].
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Autoreactive CD4+ and CD8+ T cells target against islet cells. SCs could dif-
ferentiate into insulin producing β cells. Sources of stem cells for diabetes therapy 
include embryonic stem cells (MSC), hematopoietic stem cells (HSC), and induced 
pluripotent stem cells (iPSCs). Following stem cells therapy, C-peptide secretion, 
HbA1c level, and insulin levels are monitored for better intervention of the effi-
ciency of the technique. Monitoring response of T cells to HLA-A2-retsricted insulin 
B10, pre-pro-insulin, islet antigen, GAD65 and pre-pro islet amyloid polypeptide 
might hint the efficiency of SCT [71, 72].
6.1.1 Current treatment methods
Current treatment methods focus on producing insulin to regulate the blood 
sugar level. Insulin is injected into the subject and the blood sugar level is moni-
tored at various time points. Islets cells are transplanted in certain cases along with 
immune suppression.
6.1.2 Animal model study
Soria et al. used mice model to study type 1 diabetes. In the study, mice derived 
ESCs were allowed to differentiate into insulin producing cells and were injected 
into a diabetic mouse. Secreted insulin could reverse glycaemia. Further SCT was 
also successful in streptozotocin induced diabetic mice. iPSCs obtained from mouse 
ESCs could synthesize insulin by cleaving pro-insulin into C-peptide and insulin. 
It is also evidential that ESC derived cells consisted of all β cell features except for 
production of insulin at high glucose levels [73].
Oh et al. chose BM-derived cells for their mice model. The experimenters found 
that when the medium was supplemented with DMSO and high glucose concentra-
tion, the cells transformed into insulin producing cells (IPC). Moreover, the cells 
could aggregate mimicking the islet cells. Blood sugar level regulation could be done 
up to 3 months successfully [74].
Xie et al. found that hBM-MSC were able to give rise to IPC with addition of 
Activin A. Differentiated cells could produce insulin in glucose-dependent man-
ner and could regulate blood sugar level until a month in diabetes induced  
mice [75].
6.1.3 Clinical trial study
Hu et al. performed Type 1 diabetes over three human subjects during the year 
2011. Selection criteria used for the study was that the onset period should be less 
than 60 days staying within a healthy BMI of 22. Two subjects were treated with 
BM-derived SCs delivered by liver puncture. Before the therapy, the subjects were 
positive for insulin cells Ab (ICA) and glutamic acid decarboxylase (GAD). After a 
12-month follow up, the subject was found to be negative on ICA, GAD, and insulin 
antibody. Subject’s serum also had increase in C peptide and a decline in blood 
glucose and HbA1C and glycosylated Hb.
Dr. Chen et al. studied the long-term effects of implanting Wharton’s jelly-
derived MSC (WJ-MSC) from umbilical cord. Twenty-nine subjects were used 
to participate in the study by dividing into two groups. Group 1 comprises of 
people injected with WJ-MSC and group 2 had people treated with insulin once 
in 3 months for a period of 21 months. The HbA1C and C-peptide levels were 
found to decline in group 1 subjects documenting the success of  
WJ-MSCs [76, 77].
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6.2 Multiple sclerosis
Multiple sclerosis (MS) is a neurological disability in which the myelin sheath 
around the axons of the brain and the spinal cord are demyelinated. In MS, T and B 
cells initiate the inflammatory attack. Such damage cannot be reversed and hence 
causes many complications. No current therapy has found a solution to arrest the 
progress of the disease. SCT for MS subjects was found to replace neural precur-
sors such as oligodendrocytes and myelin with attenuation in the autoimmune 
process locally [78, 79].
6.2.1 Current treatment methods
Current treatment methods include administering corticosteroids such as 
oral prednisone and intravenous methylprednisolone, oral treatments such as 
 fingolimod, dimethyl fumarate, teriflunomide, siponimod and infusion treatments 
include ocrelizumab, natalizumab, alemtuzumab, and mitoxantrone. Beta interfer-
ons, glatiramer acetate, dimethyl fumarate, fingolimod, and teriflunomide are pre-
scribed to reduce nerve inflammation. Plasma exchange (plasmapheresis) is another 
technique in which blood plasma is removed from blood cells and then mixed with 
albumin and put it back to the body. Other treatments such as physiotherapy, muscle 
relaxants (Zanaflex and Lioresal), and medications to reduce fatigue (amantadine 
and methylphenidate) are also applied when the magnitude of symptoms increase. 
Currently, stem cell therapy using MSCs or iPSCs shows great potential as treatment 
for MS. Figure 7 shows iPSC-based therapeutics for multiple sclerosis.
6.2.2 Animal model study
Deng et al. performed a murine model study in mice affected by experimental 
autoimmune encephalomyelitis (EAE). EAE shared common features with human 
model of MS. During the study, it was evidential that the injection of MSCs could 
pacify myelin oligodendrocyte glycoprotein (MOG) induced EAE. There was a 
Figure 7. 
Human iPSC-based therapeutics for multiple sclerosis.
Innate Immunity in Health and Disease
16
decline in the infiltration of T cells, B cells, and macrophages into the brain and 
spinal cord. MSCs were found to migrate to the spleen and inflamed CNS to thereby 
have a neuroprotective effect on the CNS Figure 8. Further, such a therapy was also 
found to help in oligodendrogenesis and also increased the magnitude of symptoms. 
As a result, CD8+ cells were more in the brain Deng et al. Carmen Marin-Bariasco 
et al. derived MCSs from SJL/JCrl mice. During the study, it was evidential that 
there was a modulation in the progress of the disease [80, 81].
6.2.3 Clinical trial study
The first reported AHSCT was performed on MS subjects in 1995 and re-
myelinization occurred in the damaged sites. In 2002, HSCT was performed over 
200 subjects affected with MS and there was reduction in inflammation at the 
CNS. However, complications such as infection and high T cell associated mortal-
ity and morbidity rates occurred during the study. Bonab et al. found that MSCs 
when injected intrathecally produced no adverse effects in 10 patients with non-
responsive disease. Karusis et al. proceeded with phase one and two with 10–15 
subjects. They found that there was no adverse effect produced during the follow up 
period of up to 28 months. Outcomes such as increment in CD4+, CD25+ regulatory 
T cells, decline in proliferative response of lymphocytes, and activation markers 
on dendritic cells. Connick et al. transplanted autologous MSCs in 10 subjects. The 
team found that such a therapy was found to reduce progress of general disability 
and improve visual function of subjects [82].
Figure 8. 
Stem cell treatment for mice affected with multiple sclerosis.
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Riccardo et al. performed an autologous HSCT for severe progressive multiple 
sclerosis in a multicenter trial on 19 subjects with rapidly progressive MS with a 
score up to 7 on the scale for expanded disability status. After stem cell mobilization 
with CY and filgrastim, patients were conditioned with 1,3-bis[2-chloroethyl]-
1-nitrosourea, etoposide, aracytin, melphalan, and followed by horse ATG. All 
patients showed clinical stabilization or improvement and three patients experi-
enced deteriorate as a result of transplant related complication and 1 beyond the 
baseline. Among 19 patients, no death was reported after the change of condition-
ing to CY plus ATG. These studies indicate that HSCT is able to induce a prolonged 
clinical stabilization in severe progressive MS patients, resulting in both sustained 
treatment-free periods and improved quality of life [83].
6.3 Crohn’s disease
Crohn’s disease is characterized by recurring episodes of inflammation in the 
GI tract. The exact cause for Crohn’s disease is unknown. Sources can be genetical, 
immunological, environmental, or even microbial. Hereditary transfer of Crohn’s 
disease ends up with a higher probability and the incidence is 30 times higher in 
siblings. Crohn’s disease is associated with the auto activation of T cells, especially 
Th1and Th17. Environmental factors such as dietary constituents and smoking also 
play a role in acquiring crohn’s disease. High level of interleukins such as IL-21/
IL-22, MMP 9 and fecal calprotectin are associated with the disease [84, 85].
6.3.1 Current treatment methods
On a major scale, drugs and techniques are employed to allay symptoms and 
consequences of the disease. Anti-inflammatory drugs such as corticosteroids are 
administered. Immune system suppressors are administered and drugs vary a wide 
range from cyclosporine to azathioprine. Antibiotics are and other medications such 
as anti-diarrheal, pain relievers, calcium and vitamin D supplements, vitamin B-12 
shots and iron supplement. Surgery is done in certain cases and nutrition therapy is 
also recommended in certain cases.
6.3.2 Animal model study
Both canine and mice model were used to study Crohn’s study. Cavazza et al. 
induced CD in 8-week year old mice by injecting Dextran sulfate sodium. The 
outcome obtained by the experimenters was a positive outcome, adipose-derived 
MSC could achieve the therapeutic effect and human cord derived blood platelets 
(hCBPL) were found to reduce colitis score [86].
Hoffman et al. used a dog affected with canine anal furunculosis as it had the 
same features as a human fistulizing Crohn’s disease. Human ESCs derived MSCs 
were injected into six dogs used in the study. As a result, the interleukins associated 
with Crohn’s disease (IL-2 and IL-6) were reduced after 2 months of post injection. 
After 3 months, the dogs were found completely free and after 6 months two dogs 
had relapse [87].
6.3.3 Clinical trial study
Molendijk et al. performed allogeneic bone marrow-derived mesenchymal 
stromal cells transplant to promote healing of refractory perianal fistulas in patients 
with Crohn’s Disease. About 21 patients were randomly grouped and given injec-
tions of MSCs into the wall of curettage fistula in three different cell concentration 
Innate Immunity in Health and Disease
18
and control (1 × 107 (n = 5), 3 × 107 (n = 5), and 9 × 107 (n = 5), and n = 6 of placebo 
cells). Fistula healing was observed and observed that there was nil association 
between local administration of allogenic MSCs and the adverse events in subjects 
affected by perianal fistulizing Crohn’s disease [88]. Garcia-Olmo et al. performed 
clinical trials over 10 subjects (8 males and 2 females). In six subjects, there was 
complete cessation of suppuration of the fistula. Partial response was seen in three 
subjects with decline in suppuration. A year later there was a nil score on six cases 
with two cases where the incontinence score improved from the range 12-8 to 5. Nil 
adverse effects were observed throughout the experiment [89].
Ciccocioppo et al. studied the long-term effects of MSC therapy on eight sub-
jects during a period of 7 years from 2007 to 2014. Disease remission was noted for 
up to 12 months with a gradual decline in between followed by remission again. The 
probability of a disease-free state declined from 88% in the first year to 37% in the 
last 4 years [90].
7. Trial results of stem cell therapy
Though stem cell therapy is found to be a promising solution, in the long run 
several complications follow. But there are also cases where the technique was found 
to be ineffective over certain subjects. Hence, impact of the technique as a whole is 
discussed in the following section.
A retrospective analysis of subjects affected by AID was taken into account. 
Nine hundred subjects were taken into consideration with a lead count of 345 on 
MS, followed by other AIDs such as the systemic sclerosis (175), SLE (85), RA (89), 
juvenile idiopathic arthritis (65), and idiopathic cytopenic purpura (37).
One third of the subjects responded completely while two third of the remaining 
had no response. There were 85% five-year survivals and 43% progress free survival 
during the whole period of study. On the better side, transplant related mortality 
was 1% for RA subjects while it came up to 11% for SLE and JIA. On the worse side, 
HSCT could cause acute toxicity and end up subjects with infection and bleeding. In 
Systematic Sclerosis subjects, HSCT was found to induce rapid fluid and electrolyte 
shifts. In juvenile idiopathic arthritis (JIA), fatal macrophage activation was found 
to occur as a result of immunosuppression. Though subjects were affected by fungal 
and other infections, there were also lethal outcomes due to second autoimmunity. 
Worst case scenario also included re-expression and relapse with a reduction in 
magnitude of the disease [91, 92].
8. Conclusion
Overall, this chapter highlighted the advances in the clinical use of stem cells in 
the treatment of an array of systemic and organ-specific autoimmune disorders. 
The treatment of many types of autoimmune diseases was conducted through the 
administration of autologous/allogenic HSCs and MSCs transplantation. Although 
the progress in clinical trials using stem cells in AID modification, immunomodula-
tion, and regenerative purposes are certainly encouraging, still most of the treat-
ment methods are still in the early stages. This is due to the clinical results reported 
are not clear about therapeutic efficacy and only a significant number of studies 
were conducted in humans, while most of them are conducted in animal models of 
immune-related diseases. This indicates the need for the conduction of randomized 
clinical trials in relevant immune-related diseases for the potential application of 
stem cell treatment. Due to the substantial variation among studies, comparing 
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results from one stem cell-based medicinal product to another is very challenging. 
Therefore, uniform regulation of the clinical application of stem cells is highly 
indispensable for minimally invasive, customizable and individualized therapeu-
tic method for a safe and successful treatment alternative. It is also important to 
determine the most appropriate source of stem cells that should be applied for the 
treatment of each autoimmune disease. In conclusion, despite the need for further 
studies, the treatment of immune-related diseases through the administration of 
stem cell is progressively ceasing due to many questions regarding the risks of stem 
cell application and its potential side effects that need better answers.
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